Search
Element Search
Structure Search
Thermo Scientific Chemicals
Benzotropine methanesulfonate
Muscarinic receptor antagonist | CAS: 132-17-2 | C22H29NO4S | 403.54 g/mol
Have Questions?
Change view
Catalog number J61954.03
also known as J61954-03
Price (USD)
29.60
Each
Quantity:
1 g
Price (USD)
29.60
Each
Chemical Identifiers
CAS132-17-2
Specifications
Specification Sheet
Specification SheetAppearance (Color)White to off-white
FormPowder
Assay (HPLC)≥98.0%
Infrared spectrumConforms
Benzotropine methanesulfonate is used to treat the symptoms of Parkinson?s disease and is currently in clincial trials for chronic back pain. It shows anti-muscarinic effects comparable to Atropine, and also demonstrates competitive anti-nicotinic action at the nAChR (nicotinic acetylcholine receptor).
This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
Solubility
Soluble in water (81 mg/ml at 25°C), DMSO (50 mg/ml at 25°C), ethanol (81 mg/ml at 25°C), and ether (very slightly).
Notes
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Store away from oxidizing agents. Store at 4°C.
Soluble in water (81 mg/ml at 25°C), DMSO (50 mg/ml at 25°C), ethanol (81 mg/ml at 25°C), and ether (very slightly).
Notes
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Store away from oxidizing agents. Store at 4°C.
RUO – Research Use Only
General References:
- Heidi Bisgaard; M Andreas B Larsen; Sonia Mazier; Thijs Beuming; Amy Hauck Newman; Harel Weinstein; Lei Shi; Claus J Loland; Ulrik Gether. The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology. 2011, 60, (1), 182-190.
- José A G Agúndez; Elena García-Martín; Hortensia Alonso-Navarro; Félix Javier Jiménez-Jiménez. Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opinion on Drug Metabolism and Toxicology. 2013, 9, (7), 859-874.